Effects of slow-releasing colistin microspheres on endotoxin-induced sepsis

Yuta Nanjo1, Yoshikazu Ishii, Soichiro Kimura

  • 1Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo, 143-8540, Japan.

Insights

Slow-releasing colistin microspheres reduce toxicity and improve efficacy in endotoxin-induced sepsis models. These microspheres maintain higher colistin concentrations, lower endotoxin and cytokine levels, and decrease adverse reactions compared to standard colistin sulfate.

Area of Science:

  • Pharmacology
  • Drug Delivery Systems
  • Toxicology

Background:

  • Lipopolysaccharide (LPS) is a primary cause of endotoxic shock.
  • Colistin effectively binds LPS but has limitations including adverse reactions and a short half-life.
  • Developing improved colistin formulations is crucial for managing sepsis.

Purpose of the Study:

  • To develop and evaluate slow-releasing colistin microspheres for treating endotoxin-induced sepsis.
  • To assess the toxicity, pharmacokinetics, and efficacy of colistin microspheres compared to colistin sulfate.

Main Methods:

  • Colistin microspheres were prepared using poly-lactic-co-glycolic acid.
  • Acute toxicity and nephrotoxicity were assessed in mice.
  • Pharmacokinetic analysis was performed after subcutaneous administration.
  • Efficacy was evaluated in a mouse model of LPS-induced sepsis by measuring serum endotoxin and spleen cytokine levels.

Main Results:

  • Colistin microspheres demonstrated reduced acute toxicity and nephrotoxicity compared to colistin sulfate.
  • Higher plasma colistin concentrations were observed at 12 and 24 hours post-administration for microspheres.
  • Colistin microspheres significantly reduced serum endotoxin levels at 24 hours.
  • Reduced endotoxin levels correlated with lower spleen cytokine levels, indicating reduced inflammation.

Conclusions:

  • Slow-releasing colistin microspheres offer a promising alternative to colistin sulfate for sepsis treatment.
  • This formulation enhances colistin's pharmacokinetic profile and reduces associated toxicity.
  • Colistin microspheres effectively mitigate endotoxin and cytokine storm in endotoxin-induced sepsis.